Introduction
Human induced pluripotent stem cells (hiPSCs) are human somatic cells that are genetically reprogrammed into an embryonic-like, pluripotent state capable of differentiating into all three germ layers. Since the original description of induced pluripotent stem cells (iPSCs), 1 the field has greatly expanded. [2] [3] [4] The hiPSC technology has the potential to revolutionize regenerative and precision medicine by providing differentiated cells for cell-based therapy, disease modeling, drug testing, and high-throughput drug discovery in a patient-specific manner.
A large number of studies have refined the techniques for efficient directeddifferentiation of hiPSCs into cardiomyocytes. 5 In addition, multiple studies have provided evidence for the application of hiPSC-derived cardiomyocytes (hiPSC-CMs)
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Yamoah et al in cardiac transplantation in animal models. 6 One of the main advantages of utilizing hiPSC-CMs, as opposed to undifferentiated hiPSCs, is the elimination of the risk of teratoma formation. Moreover, hiPSC-CMs serve as an unlimited source of committed human cardiomyocytes.
Genetic modification of hiPSCs represents an essential tool for the study of hiPSCs. Expression of different markers is required in cell-based therapy applications of hiPSCs and hiPSC-CMs. With the advent of genome editing using CRISPR-Cas9 technology, 7 it has become increasingly feasible to correct disease-causing mutations in patient-specific hiPSCs, in order to create isogenic lines for disease modeling or potential therapeutics. However, there are significant technical challenges for the transfection of hiPSCs and hiPSC-CMs, since these cells are known to be difficult to transfect. [8] [9] [10] Although multiple methods of genetic modifications exist (ie, nucleofection, lipofectamine-mediated transfection, and viral-based transduction), their efficiency, cytotoxicity, safety, and cost remain unsatisfactory. 8 Increasingly, nanoparticles (NPs) have been used in biomedical research as powerful tools for drug delivery and personalized medicine. 11 The objective of this study is to examine the efficiency of gene transfection in hiPSCs and hiPSC-CMs using magnetic NPs. Our study offers a novel approach to introduce desired genes into hiPSCs and hiPSC-CMs without the need for viral vector generation.
Materials and methods cell culture
HiPSCs (19-9-7T and 6-9-9, WiCell, Madison, WI, USA) were plated in feeder-free conditions using matrigel-coated culture dishes and chemically defined medium, mTeSR™ 1 (Stemcell Technologies, Inc., Cambridge, MA, USA). Cardiac myocytes were generated using a directed differentiation protocol. 12 Briefly, differentiation of confluent (80%-90%) cells was initiated by adding RPMI/B27 medium (Thermo Fisher Scientific, Waltham, MA, USA) lacking insulin and containing the CHIR99021 (Tocris, Minneapolis, MN, USA) for 24 hours, followed by RPMI/B27 media with an inhibitor of Wnt signaling, IWR-1-endo (Tocris). Differentiated hiPSCs were replated on a coverslip prior to transfection and action potential (AP) recordings.
Magnetic-assisted transfection using nanoparticles
The transfection was conducted following the manufacturer's instructions (Neuromag, OZ Biosciences Inc., San Diego, CA, USA) and published methods. 13, 14 The NPs are positively charged, with a zeta .+30 mV in water. The size of the NPs ranges from 140 to 200 nm with the majority around 160 nm, and the particle population is rather homogeneous. Briefly, plasmid DNAs (pIRES2-EGFP, Clontech Laboratories, Inc., Mountain View, CA, USA) or a double fusion construct (an integrating vector) with green fluorescence protein (GFP) 15 were diluted in cell culture medium, and the NP reagent was added to the culture medium containing DNA. DNA handling followed NIH guidelines. After brief vortexing and 20-minute incubation at room temperature, the medium containing the DNA/nanoparticle complexes was added to the cell culture dish. The dish was then placed on a magnetic plate and incubated in a cell culture incubator for 1, 2, and 4 hours. Cells were harvested or differentiated after 24-48 hours of transfection. For comparison, lipofectamine-2000 and -3000 (Thermo Fisher Scientific) were used.
Flow cytometric analysis
Cells were trypsinized and analyzed for GFP signal using a standard FACScan cytometer (BD Biosciences, San Jose, CA, USA), as we have described. 16 Briefly, cells were fixed with 0.4% paraformaldehyde (PFA) before treating with anti-myosin heavy chain antibody (Developmental Studies Hybridoma Bank, Iowa city, IA, USA) in PBS with 5% donkey serum and 20 µg/mL DNAse-free RNAse (SigmaAldrich Co., St Louis, MO, USA), overnight at 4°C. Cells were also stained with 40 µg/mL 7-amino-actinomycin D (7AAD, BD Biosciences) to measure the DNA content. Data were collected using a standard FACScan cytometer (BD Biosciences) upgraded to a dual laser system with the addition of a blue laser (15 mW at 488 nm) and a red laser (25 mW at 637 nm Cytek Development, Inc., Fremont, CA, USA). Data were acquired using CellQuest software (BD Biosciences) and analyzed using FlowJo software (Ver9.4 Treestar Inc., San Carlos, CA, USA). Cells stained with isotype-matched IgG antibodies were used as controls to determine the positive cell population.
Immunofluorescence confocal microscopy
Expression of troponin T in hiPSC-CMs was detected by using mouse monoclonal anti-cardiac troponin T antibody (Abcam, Burlingame, CA, USA). Images were taken using Zeiss LSM 700 confocal microscope (Carl Zeiss, Oberkochen, Germany).
electrophysiologic recordings
Spontaneous action potentials (APs) of hiPSC-CMs were recorded using the perforated-patch recording technique at 35°C, as we have described. 17 Briefly, the patch-pipettes 
Results
Efficient transfection of hiPSCs using magnetic nanoparticles
NPs have recently been used as powerful tools for drug and gene delivery. 11, 18 Magnetic NPs have been successfully used for transfection of difficult-to-transfect primary neurons. 13, 14 However, the use of magnetic NPs for transfection of hiPSCs remains unknown. We therefore tested the transfection of hiPSCs using magnetic nanoparticles. Figure 1A shows a diagram depicting magnet-assisted transfection (magnetotransfection) using NPs. A schematic representation of the experimental protocol is shown in Figure 1B . We first tested the double fusion construct, and the confocal microscopic images of transfected cells are shown in Figure 1C . Flow cytometric analyses were used to directly quantify nanoparticle-mediated transfection in HEK 293 cells and hiPSCs ( Figure 1D and E). We further tested the transfection using a non-integrating GFP construct (pIRES2-EGFP) and optimized the time needed for magnetotransfection ( Figure 1F and G). We note a significant increase in percentages of GFP-positive hiPSCs using 4 hours 
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Transfection with NPs did not alter the differentiation of hiPscs to hiPsc-cMs
One possible concern using magnetotransfection is whether the procedure may alter the differentiation efficiency of hiPSCs. Here, we directly compared the differentiation efficiency between control (non-transfected) and transfected hiPSCs into cardiomyocytes (CMs). The differentiated CMs exhibited large beating clusters with spontaneous firing APs, consistent with populations of ventricular-like, atrial-like, and nodal-like APs (Figure 2A and B) . 19 There were no significant differences in the efficiency of differentiation into CMs between control hiPSCs and GFP-transfected hiPSCs using NPs ( Figure 2C and D).
Magnetotransfection was more efficient than lipofectamine in hiPsc-cMs
HiPSCs can be differentiated into multiple cell types. HiPSC-CMs have potential for many applications in cardiac regeneration, as well as serving as models for cardiovascular diseases. 6, 20 HiPSC-CMs, as differentiated cells, are even more difficult to transfect compared to hiPSCs. It is critical to further evaluate the efficiency of magnetotransfection in hiPSC-CMs. By using flow cytometric analysis of both myosin heavy chain (MyHC) and GFP positive cells, we directly demonstrated that magnetotransfection was more efficient than lipofectamine not only in hiPSCs, but also in hiPSCCMs ( Figure 2E and F) using pIRES2-EGFP construct.
Discussion
Since the original description of iPSCs, 1 the wide-reaching potentials of the technology have been rapidly realized for 
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Transfection of hiPscs by magnetic nanoparticles both regenerative and precision medicine. The utilization of hiPSCs enables the development of an unlimited source of any human cell types needed for therapeutic and precision medicine. Genetic modification and expression of different reporters are essential for studies to evaluate cell-based therapy applications of hiPSCs and hiPSC-CMs. However, significant technical challenges exist for the transgene delivery into hiPSCs. [8] [9] [10] Several methods have been developed for transgene delivery, which are mainly catogorized into viral and non-viral methods. [8] [9] [10] Three types of viral vectors are widely used in the transgene delivery, including adenoviral, lentiviral, and adeno-associated viral vectors. The advantage of viral vectors lies in their high delivery efficacy, but their use also raises safety concerns including the cytotoxicity, cellular immune responses, and transgene integration into host genome. Non-viral methods, including mechanical and electrical methods such as injection or electroporation, and chemical methods such as lipofection, are potentially safer alternatives for transgene delivery into iPSCs, but the transfection efficiency is relatively lower.
9,10
For iPSC-CMs and embryonic stem cell-derived cardomyocytes (ESC-CMs), viral transduction and nucleofection are commonly used for transgene delivery. [21] [22] [23] [24] Magnetic NPs have been used for the transfection of cell lines and primary cells including neurons. 13, 14, 25 Magnetic nanoparticle-mediated gene transfer offers significant advantages over other gene transfer methods, such as high efficiency, low cytotoxicity, low cost, directional and distal controllability, efficient in vivo applications, and lack of immune responses. [25] [26] [27] [28] Recently, magnetic NPs have been used for gene delivery to neural precursor/stem cells. 26, 27, 29 However, whether magnetic nanoparticles can be efficiently used for transfection of iPSCs and iPSC-CMs has not been addressed and reported. Here, we demonstrate that the difficult-to-transfect hiPSCs and hiPSC-CMs can be efficiently transfected using magnetic NPs.
Our study offers a novel approach to introduce transgenes into hiPSCs and hiPSC-CMs without the need for viral vector generation. Indeed, our findings transcend the benefits for hiPSCs and hiPSC-CMs. The technique may represent a non-viral method for the generation of hiPSCs and thus avoid the risk of genomic insertions inherent in some integrating viral methods. The potential application will be the genetic modification of hiPSCs and hiPSC-CMs for in vitro guided differentiation and in vivo transplantation for tissue regeneration and repair. The distal control of nanoparticles by a magnetic field will further potentiate the in vivo application and delivery of nucleic acids to specific organs for targeted gene therapy. The possible limitation may come from the cytotoxicity of magnetic NPs, which results from the accumulation of NPs in endosomes and/or vacuoles in cells. However, NPs will be degraded through normal iron metabolism over time, although the mechanism is still not well understood. 11, 25 For future studies, transfection efficiencies between different types of constructs need to be addressed.
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